LDDN Projects
|
Project |
Project Status |
|||||||
|
1 |
2 |
3 |
4 |
5 |
6 |
7 |
||
|
1 |
Inhibitors of cdk5/p25-Catalyzed Phosphorylation of Tau |
X |
X |
X |
X |
X |
X |
X |
|
2 |
Activators of Peptide-Exchange on MHC II |
X |
X |
X |
X |
X |
X |
X |
|
3 |
Inhibitors of EphB3 Kinase (Yr1)a |
X |
X |
X |
X |
X |
X |
X |
|
4 |
Expression of Survival Motor Neuron (SMN) |
X |
X |
X |
X |
X |
X |
X |
|
5 |
Activation of Glu Transporter EAAT2 Expression (Yr2) |
X |
X |
X |
X |
X |
X |
X |
|
6 |
Activators of Atoh1 (Yr2) |
X |
X |
X |
X |
X |
X |
|
|
7 |
Inhibition of STEP (Yr3) |
X |
X |
X |
X |
X |
X |
X |
|
8 |
Inhibition of BACE1 in Neuronal Cells (Yr3) |
X |
X |
X |
X |
X |
X |
|
|
9 |
Inhibition of Kinase & GTPase Activities of LRRK2 (Yr3) |
X |
X |
X |
X |
X |
||
|
10 |
Enhancers of Expression of BRCA1 (Yr3) |
X |
X |
X |
X |
X |
|
|
|
11 |
Activators of Klotho |
X |
X |
X |
X |
|||
|
12 |
Inhibition of Interaction between mSOD1 and Dynein (Yr4) |
X |
|
|
|
|
|
|
|
13 |
Inhibition of Ero1 Sulfhydryl Oxidase (Yr4) |
X |
X |
X |
X |
|||
|
14 |
Activators of PGC-1a (Yr4) |
X |
X |
X |
X |
|
|
|
|
15 |
Inhibition of Lyn Kinase (Yr4) |
X |
||||||
|
16 |
Inhibitors of APP dimerization (Yr4) |
X |
|
|||||
|
17 |
Stimulation of Microglia Generation (CADDIb) |
X |
||||||
|
18 |
Inhibition of TDP-43 Generation (CADDI) |
X |
||||||
|
19 |
Modulators of the Expression of B-Synuclein |
|
||||||
|
20 |
Modulators of Insulin-Degrading Enzyme |
|||||||
|
21 |
Modulators of UCH-L1 Activity |
|||||||
|
22 |
Inhibitors of Tissue Transglutaminase |
|||||||
|
23 |
Inhibitors of Processing of Amyloid-B Precursor |
|||||||
|
24 |
Necrosis Inhibitors |
licensed IP |
||||||
(a) Year of participation of post-doctoral fellow in the NIH-funded National Center for Drug Discovery in Neurodegeneration (Yr1 was from Fall 2005 – Fall 2006).
(b) Project sponsored by the Collaborative ALS Drug Discovery Initiative (CADDI).
(c) Dormant projects have shown good performance in HTS, but have not produced a lead structure.
Key for Status
- Assay development is underway.
- Assay has been developed and validated.
- Assay development complete; shaded 'X' signifies screen underway.
- Hits were discovered during screen.
- Screening hits were validated and medicinal chemistry is pending.
- Medicinal chemistry program has been launched.
- Animal efficacy or pharmacokinetic studies.
Download a PDF of project details here.
